Brown Brothers Harriman & Co’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-25
| Closed | -$2.88K | – | 1538 |
|
|
2024
Q3 | $2.88K | Buy |
+25
| New | +$2.88K | ﹤0.01% | 1250 |
|
|
2023
Q4 | – | Sell |
-18
| Closed | -$2.03K | – | 1233 |
|
|
2023
Q3 | $2.03K | Hold |
18
| – | – | ﹤0.01% | 1104 |
|
|
2023
Q2 | $1.7K | Hold |
18
| – | – | ﹤0.01% | 1143 |
|
|
2023
Q1 | $1.82K | Sell |
18
-249
| -93% | -$25.2K | ﹤0.01% | 1162 |
|
|
2022
Q4 | $31.9K | Sell |
267
-164
| -38% | -$19.6K | ﹤0.01% | 796 |
|
|
2022
Q3 | $46K | Buy |
431
+182
| +73% | +$19.4K | ﹤0.01% | 758 |
|
|
2022
Q2 | $24K | Buy |
+249
| New | +$24K | ﹤0.01% | 845 |
|
|
2020
Q2 | – | Sell |
-6
| Closed | -$1K | – | 1117 |
|
|
2020
Q1 | $1K | Hold |
6
| – | – | ﹤0.01% | 1024 |
|
|
2019
Q4 | $1K | Sell |
6
-4
| -40% | -$667 | ﹤0.01% | 1075 |
|
|
2019
Q3 | $1K | Hold |
10
| – | – | ﹤0.01% | 1140 |
|
|
2019
Q2 | $1K | Buy |
+10
| New | +$1K | ﹤0.01% | 1040 |
|
|
2018
Q3 | – | Sell |
-25
| Closed | -$2K | – | 864 |
|
|
2018
Q2 | $2K | Hold |
25
| – | – | ﹤0.01% | 781 |
|
|
2018
Q1 | $2K | Sell |
25
-31
| -55% | -$2.48K | ﹤0.01% | 755 |
|
|
2017
Q4 | $4K | Buy |
+56
| New | +$4K | ﹤0.01% | 892 |
|
|
2017
Q1 | – | Sell |
-92
| Closed | -$4K | – | 851 |
|
|
2016
Q4 | $4K | Hold |
92
| – | – | ﹤0.01% | 785 |
|
|
2016
Q3 | $5K | Hold |
92
| – | – | ﹤0.01% | 686 |
|
|
2016
Q2 | $4K | Buy |
+92
| New | +$4K | ﹤0.01% | 735 |
|